EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Immunogenicity and safety of measles-mumps-rubella vaccine delivered by the aerosol, intradermal and intramuscular routes in previously vaccinated young adults: a randomized controlled trial protocol

Sumanta Saha iD, Melanie Millier, Ari Samaranayaka, Liza Edmonds, Emma Best iD, James Ussher iD, Andrew Anglemyer, Jennifer Lee, Michael Tatley, Felicity Cutts, Rob van Binnendijk, Peter McIntyre

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0318893 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2025. Verfasst von Sumanta Saha und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Otago, Otago New Zealand. Hauptthemen laut MEDLINE: Immunogenicity, Vaccine, Measles, Measles-Mumps-Rubella Vaccine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, Ministry of Business, Innovation and Employment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are increasing reports of outbreaks of measles in countries that achieved measles elimination using two doses of measles-mumps-rubella (MMR) vaccine, particularly in health care settings. While responses to a third dose of MMR in two-dose recipients have been examined, these studies have all administered MMR by the standard (intramuscular or subcutaneous) route, and data on the duration of antibody are limited. We have developed a protocol for an open-label parallel-arm randomized-controlled trial to compare measles antibody responses and safety after intradermal and aerosol administration of MMR with intramuscular, the usual mode of administration in Aotearoa (New Zealand).

Methods

Eligible participants are aged ≥ 18 years who have previously received two doses of the MMR vaccine and based on levels of IgG antibody to measles or mumps below the threshold for seropositivity in commercially available screening tests are required to receive the MMR vaccine prior to entering health professional training programs at Aotearoa universities. The participants will be randomized to three routes of administration (1:1:1) to receive the MMR vaccine by the intradermal (via microneedle), intrapulmonary (via vibrating mesh nebulizer), or intramuscular routes. The primary objective is to determine the proportion of participants who attain levels of measles IgG antibody above the seroprotective threshold using a multiplex bead-based immunoassay, with those in the lowest quartile validated by plaque neutralization assay, at days 6–8, 13–15, 28–42, and at 12–18 months post-vaccination. Secondary objectives include a fold increase in the geometric mean concentration of IgG antibody from baseline, and systemic and local reactions following delivery of MMR by each method. The trial is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR; https://www.anzctr.org.au/Default.aspx ; trial registration no. ACTRN12623000130662).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunogenicity, VaccineMeaslesMeasles-Mumps-Rubella VaccineAdolescentAdultFemaleHumansMaleYoung AdultAerosolsAntibodies, ViralInjections, IntradermalInjections, IntramuscularNew ZealandVaccinationRandomized Controlled Trials as Topic

Substanzen

AerosolsAntibodies, ViralMeasles-Mumps-Rubella Vaccine

Autor:innen und Institutionen

  • University of Otago, Otago New Zealand.
  • Victoria University, Wellington New Zealand.
  • The University of Auckland, Auckland New Zealand.
  • The London School of Hygiene & Tropical Medicine, Bloomsbury, UK.
  • National Institute for Public Health and the Environment, Bilthoven The Netherlands.

ORCID-Profile: Sumanta Saha, Emma Best, James Ussher

Förderung

  • Health Research Council of New Zealand
  • Ministry of Business, Innovation and Employment

Zitieren

APA

Saha, S., Millier, M., Samaranayaka, A., Edmonds, L., Best, E., Ussher, J., Anglemyer, A., Lee, J., Tatley, M., Cutts, F., van Binnendijk, R., & McIntyre, P. (2025). Immunogenicity and safety of measles-mumps-rubella vaccine delivered by the aerosol, intradermal and intramuscular routes in previously vaccinated young adults: a randomized controlled trial protocol. PLOS ONE. https://doi.org/10.1371/journal.pone.0318893

Vancouver

Saha S, Millier M, Samaranayaka A, Edmonds L, Best E, Ussher J, et al. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by the aerosol, intradermal and intramuscular routes in previously vaccinated young adults: a randomized controlled trial protocol. PLOS ONE. 2025. doi:10.1371/journal.pone.0318893

BibTeX
@article{Saha2025,
  author = {Saha, Sumanta and Millier, Melanie and Samaranayaka, Ari and Edmonds, Liza and Best, Emma and Ussher, James and Anglemyer, Andrew and Lee, Jennifer and Tatley, Michael and Cutts, Felicity and van Binnendijk, Rob and McIntyre, Peter},
  title = {Immunogenicity and safety of measles-mumps-rubella vaccine delivered by the aerosol, intradermal and intramuscular routes in previously vaccinated young adults: a randomized controlled trial protocol},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0318893}
}
Kostenlos starten →